Andrew Bascand, Managing Director of Harbour Asset Management joins me to discuss new findings of the GLP-1 drug class, which has predominantly been used to treat type 2 diabetes but has captured notable mindshare with healthcare specialists and macro investors.
Listen in for your chance to get ahead of the markets.
LISTEN ABOVE

Amanda Morrall: Saving money with rising costs
41:07

Rupert Carlyon: Global tension? Ignore your KiwiSaver
40:24

Chris Wilson: KiwiSaver changes need some tweaking
41:28